Selank
(Synthetic Heptapeptide – Anxiolytic & Cognitive Modulator)
Selank is a synthetic heptapeptide analog derived from the endogenous tuftsin sequence, engineered to modulate neuropeptide activity within the central nervous system. Developed as a stable, longer-acting variant of tuftsin, Selank has been extensively evaluated in preclinical and early-phase clinical studies for its neuromodulatory, nootropic, and anxiolytic properties.
Research indicates that Selank may influence key pathways involved in mood regulation, cognitive performance, and stress response, with particular interest in its ability to modulate monoamine neurotransmitters and suppress anxiety-related behaviors in experimental models.
Mechanism of Action (Based on Preclinical and Clinical Research):
Regulation of neurotransmitters:
Modulates serotonin, dopamine, and norepinephrine levels in the CNS, supporting balanced neurochemical signaling.
GABAergic influence:
Demonstrates indirect effects on GABA activity, contributing to its observed anxiolytic properties without sedative characteristics.
Tuftsin-based immunomodulation:
Enhances immune system regulation by interacting with tuftsin receptors involved in immune homeostasis.
BDNF upregulation:
Promotes increased expression of Brain-Derived Neurotrophic Factor (BDNF), supporting synaptic plasticity and cognitive function.
Stress-response modulation:
Reduces expression of anxiety markers and normalizes behavioral responses under induced stress conditions in animal models.
Potential Benefits (Based on Preclinical Research):
-
Reduced anxiety-like behavior without sedation
-
Enhanced focus, memory, and cognitive processing
-
Increased BDNF expression and neuroplasticity support
-
Improved stress resilience and emotional regulation
-
Investigated for synergistic use with nootropic peptides (e.g., Semax)
For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.
Reviews
There are no reviews yet.